$CHRS
Coherus BioSciences, Inc. Stock $chrs

$chrs Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000155837022001764 Filed on February 23, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$73.37M	$326.6M	$110.4M
YoY Change	-33.54%	-31.37%	-10.86%
Cost Of Revenue	$12.10M	$57.59M	$11.70M
YoY Change	3.45%	52.9%	50.0%
Gross Profit	$61.27M	$269.0M	$98.70M
YoY Change	-37.93%	-38.62%	-14.95%
Gross Profit Margin	83.5%	82.36%	89.4%
Selling, General & Admin	$50.05M	$169.7M	$37.70M
YoY Change	32.76%	22.03%	4.43%
% of Gross Profit	81.69%	63.1%	38.2%
Research & Development	$50.76M	$363.1M	$44.60M
YoY Change	13.82%	154.35%	27.79%
% of Gross Profit	82.85%	135.0%	45.19%
Depreciation & Amortization	$836.0K	$3.454M	$900.0K
YoY Change	-7.11%	19.1%	-18.18%
% of Gross Profit	1.36%	1.28%	0.91%
Operating Expenses	$100.8M	$532.8M	$82.30M
YoY Change	22.5%	89.05%	4.41%
Operating Profit	-$39.55M	-$263.9M	$16.40M
YoY Change	-341.14%	-268.79%	-55.95%
Interest Expense	-$5.793M	$22.96M	-$5.700M
YoY Change	1.63%	8.47%	26.67%
% of Operating Profit			-34.76%
Other Income/Expense, Net	-$385.0K	-$283.0K	$0.00
YoY Change		-151.08%	-100.0%
Pretax Income	-$45.73M	-$287.1M	$10.80M
YoY Change	-523.38%	-311.56%	-73.85%
Income Tax	$0.00	$0.00	$1.100M
% Of Pretax Income			10.19%
Net Earnings	-$45.73M	-$287.1M	$9.700M
YoY Change	-571.39%	-317.1%	-75.27%
Net Earnings / Revenue	-62.32%	-87.92%	8.79%
Basic Earnings Per Share		-$3.81
Diluted Earnings Per Share	-$595.0K	-$3.81	$110.5K
COMMON SHARES
Basic Shares Outstanding	76.79M	75.45M	72.05M
Diluted Shares Outstanding		75.45M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$417.2M	$417.2M	$541.2M
YoY Change	-22.91%	-22.91%	204.56%
Cash & Equivalents	$417.2M	$417.2M	$541.2M
Short-Term Investments	$0.00
Other Short-Term Assets	$24.46M	$24.46M	$25.00M
YoY Change	-2.14%	-2.14%	85.19%
Inventory	$37.64M	$37.64M	$44.23M
Prepaid Expenses
Receivables	$123.0M	$123.0M	$157.0M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$602.3M	$602.3M	$767.5M
YoY Change	-21.52%	-21.52%	123.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.813M	$16.01M	$10.11M
YoY Change	-22.7%	-20.37%	73.08%
Goodwill	$943.0K		$943.0K
YoY Change	0.0%		0.0%
Intangibles	$2.620M		$2.620M
YoY Change	0.0%		0.0%
Long-Term Investments
YoY Change
Other Assets	$10.03M	$57.44M	$12.54M
YoY Change	-20.07%	13.75%	3364.92%
Total Long-Term Assets	$77.01M	$77.01M	$74.17M
YoY Change	3.83%	3.93%	12.52%
TOTAL ASSETS
Total Short-Term Assets	$602.3M	$602.3M	$767.5M
Total Long-Term Assets	$77.01M	$77.01M	$74.17M
Total Assets	$679.3M	$679.3M	$841.6M
YoY Change	-19.29%	-19.28%	105.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.16M	$16.16M	$15.20M
YoY Change	6.3%	6.31%	-41.5%
Accrued Expenses	$48.13M	$148.4M	$26.68M
YoY Change	80.39%	14.88%	54.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$741.0K	$741.0K	$600.0K
YoY Change	23.5%	23.5%
Total Short-Term Liabilities	$165.3M	$165.3M	$145.7M
YoY Change	13.51%	13.47%	26.69%
LONG-TERM LIABILITIES
Long-Term Debt	$408.8M	$408.8M	$404.9M
YoY Change	0.96%	0.96%	126.96%
Other Long-Term Liabilities	$750.0K	$7.503M	$1.051M
YoY Change	-28.64%	-25.71%
Total Long-Term Liabilities	$750.0K	$416.3M	$1.051M
YoY Change	-28.64%	0.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$165.3M	$165.3M	$145.7M
Total Long-Term Liabilities	$750.0K	$416.3M	$1.051M
Total Liabilities	$581.6M	$581.6M	$560.7M
YoY Change	3.73%	3.73%	84.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.050B		-$762.8M
YoY Change	37.64%		-14.78%
Common Stock	$7.000K		$7.000K
YoY Change	0.0%		-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$97.73M	$97.73M	$281.0M
YoY Change
Total Liabilities & Shareholders Equity	$679.3M	$679.3M	$841.6M
YoY Change	-19.29%	-19.28%	105.82%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$45.73M	-$287.1M	$9.700M
YoY Change	-571.39%	-317.1%	-75.27%
Depreciation, Depletion And Amortization	$836.0K	$3.454M	$900.0K
YoY Change	-7.11%	19.1%	-18.18%
Cash From Operating Activities	-$52.32M	-$37.43M	$33.10M
YoY Change	-258.07%	-124.28%	85.96%
INVESTING ACTIVITIES
Capital Expenditures	-$468.0K	$1.289M	-$900.0K
YoY Change	-48.0%	-82.17%	125.0%
Acquisitions
YoY Change
Other Investing Activities	$108.0M	-$137.1M	$211.0M
YoY Change	-48.84%	1804.46%	-3801.75%
Cash From Investing Activities	$107.5M	-$138.4M	$210.1M
YoY Change	-48.84%	861.11%	-3601.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$40.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.487M	51.88M	5.500M
YoY Change	-72.96%	-76.83%	358.33%
NET CHANGE
Cash From Operating Activities	-52.32M	-37.43M	33.10M
Cash From Investing Activities	107.5M	-138.4M	210.1M
Cash From Financing Activities	1.487M	51.88M	5.500M
Net Change In Cash	56.65M	-124.0M	248.7M
YoY Change	-77.22%	-134.08%	1813.08%
FREE CASH FLOW
Cash From Operating Activities	-$52.32M	-$37.43M	$33.10M
Capital Expenditures	-$468.0K	$1.289M	-$900.0K
Free Cash Flow	-$51.85M	-$38.72M	$34.00M
YoY Change	-252.51%	-126.36%	86.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.coherus.com/20211231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.coherus.com/20211231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001512762
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3615821
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	76930096
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72513348
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36721
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5934000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3518000
CY2021	dei	Entity Registrant Name EntityRegistrantName	Coherus BioSciences, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	333 Twin Dolphin Drive
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	815000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	767479000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7813000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10108000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	55610000
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2021	dei	City Area Code CityAreaCode	650
CY2021	dei	Local Phone Number LocalPhoneNumber	649 - 3530
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	CHRS
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	836606033
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	77275299
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Redwood City, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	417195000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	541158000
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	123022000
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	157046000
CY2021Q4	us-gaap	Inventory Net InventoryNet	37642000
CY2020Q4	us-gaap	Inventory Net InventoryNet	44233000
CY2021Q4	chrs	Prepaid Manufacturing Expense Current PrepaidManufacturingExpenseCurrent	13666000
CY2020Q4	chrs	Prepaid Manufacturing Expense Current PrepaidManufacturingExpenseCurrent	19429000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10798000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5613000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	602323000
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	47956000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2620000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2620000
CY2021Q4	us-gaap	Goodwill Goodwill	943000
CY2020Q4	us-gaap	Goodwill Goodwill	943000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10025000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12543000
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	79885000
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	27120000
CY2020Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	26628000
CY2021Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	224288000
CY2020Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	223029000
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	75513000
CY2020Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	74481000
CY2021Q4	chrs	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	7251000
CY2020Q4	chrs	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	9948000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	750000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1051000
CY2021Q4	us-gaap	Liabilities Liabilities	581608000
CY2020Q4	us-gaap	Liabilities Liabilities	560675000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76930096
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72513348
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	7000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1147843000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1043991000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-270000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-270000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1049854000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-762754000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	97726000
CY2021Q4	us-gaap	Assets Assets	679334000
CY2020Q4	us-gaap	Assets Assets	841649000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16159000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15201000
CY2021Q4	chrs	Accrued Rebates Fees And Reserve Current AccruedRebatesFeesAndReserveCurrent	79027000
CY2020Q4	chrs	Accrued Rebates Fees And Reserve Current AccruedRebatesFeesAndReserveCurrent	81529000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22014000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22244000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	48127000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	26679000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	165327000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	145653000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	81359000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	280974000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	679334000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	841649000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	326551000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	475824000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	356071000
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	132532000
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	89557000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-38591000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	89833000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	57591000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37667000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17078000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	363105000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	142759000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	94188000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	169713000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	139079000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	137037000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	590409000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	319505000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	248303000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-263858000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	156319000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	107768000
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	2541000
CY2020	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	2498000
CY2019	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	2457000
CY2021	us-gaap	Interest Expense InterestExpense	22959000
CY2020	us-gaap	Interest Expense InterestExpense	21166000
CY2019	us-gaap	Interest Expense InterestExpense	17601000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-283000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	554000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2608000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-287100000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	135707000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	92775000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3463000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2942000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-287100000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	132244000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	89833000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.81
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.85
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.29
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.81
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.62
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.23
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75449632
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71411705
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69679916
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75449632
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83491898
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73185943
CY2021	us-gaap	Profit Loss ProfitLoss	-287100000
CY2020	us-gaap	Profit Loss ProfitLoss	132244000
CY2019	us-gaap	Profit Loss ProfitLoss	89833000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	288000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-276000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-287100000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8228000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35218000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	105214000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	132244000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17061000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3801000
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	880000
CY2021	chrs	Purchase Of Capped Call Options Relates To Convertible Notes Value PurchaseOfCappedCallOptionsRelatesToConvertibleNotesValue	-18170000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39038000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	280974000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-287100000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10410000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3002000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	40903000
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1753000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	51290000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	97726000
CY2021	us-gaap	Profit Loss ProfitLoss	-287100000
CY2020	us-gaap	Profit Loss ProfitLoss	132244000
CY2019	us-gaap	Profit Loss ProfitLoss	89833000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3454000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2888000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3259000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	51364000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	38160000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	33591000
CY2021	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	-3210000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	5133000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	2171000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	395000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1095000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	155000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	165000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4257000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3481000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2339000
CY2021	chrs	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	2207000
CY2020	chrs	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	2081000
CY2019	chrs	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	1789000
CY2021	chrs	Upfront License Fee Payments Related To License And Collaboration Arrangements UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements	136000000
CY2020	chrs	Upfront And Milestone Based License Fee Payments UpfrontAndMilestoneBasedLicenseFeePayments	7500000
CY2019	chrs	Upfront And Milestone Based License Fee Payments UpfrontAndMilestoneBasedLicenseFeePayments	11075000
CY2021	chrs	Other Noncash Adjustments OtherNoncashAdjustments	588000
CY2020	chrs	Other Noncash Adjustments OtherNoncashAdjustments	426000
CY2019	chrs	Other Noncash Adjustments OtherNoncashAdjustments	562000
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-34062000
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	15218000
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	141992000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6253000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	38359000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	48579000
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3828000
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	10851000
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	672000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5351000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2020000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2474000
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	874000
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-9820000
CY2019	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	9893000
CY2021	chrs	Increase Decrease In Accrued Rebates Fees And Reserve IncreaseDecreaseInAccruedRebatesFeesAndReserve	-2502000
CY2020	chrs	Increase Decrease In Accrued Rebates Fees And Reserve IncreaseDecreaseInAccruedRebatesFeesAndReserve	30409000
CY2019	chrs	Increase Decrease In Accrued Rebates Fees And Reserve IncreaseDecreaseInAccruedRebatesFeesAndReserve	51120000
CY2021	chrs	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-230000
CY2020	chrs	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	6212000
CY2019	chrs	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	10035000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	17932000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4996000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8346000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37432000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	154145000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	28355000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1289000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7231000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1822000
CY2020	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	175000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	182485000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	273845000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20235000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	99692000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	274000000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	20400000
CY2021	chrs	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	81672000
CY2021	chrs	Upfront And Milestone Payments Related To License And Collaboration Arrangements UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements	136000000
CY2020	chrs	Upfront And Milestone Based License Fee Payments Investing Activities UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities	7500000
CY2019	chrs	Upfront And Milestone Based License Fee Payments Investing Activities UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities	11075000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-138410000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14401000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12732000
CY2019	chrs	Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts	8153000
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	222156000
CY2020	chrs	Payments To Acquire Capped Call Options Related To Convertible Debt PaymentsToAcquireCappedCallOptionsRelatedToConvertibleDebt	18170000
CY2019	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	72955000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40903000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10399000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17428000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5558000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3002000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3801000
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3519000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1753000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	880000
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	815000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	672000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	389000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51879000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	223946000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	89370000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-276000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-123963000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	363690000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	104717000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	541598000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177908000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73191000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	417635000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	541598000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177908000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	18684000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	16959000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	15263000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	1221000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	3953000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	1732000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	434000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1388000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5267000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	477000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1817000
CY2021	chrs	Purchase Of Property And Equipment In Accounts Payable And Accrued Liabilities PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedLiabilities	119000
CY2020	chrs	Purchase Of Property And Equipment In Accounts Payable And Accrued Liabilities PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedLiabilities	109000
CY2019	chrs	Purchase Of Property And Equipment In Accounts Payable And Accrued Liabilities PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedLiabilities	999000
CY2020	chrs	Non Cash Bonus Payment Settled In Common Stock NonCashBonusPaymentSettledInCommonStock	1498000
CY2019	chrs	Non Cash Bonus Payment Settled In Common Stock NonCashBonusPaymentSettledInCommonStock	1350000
CY2021Q4	chrs	Product Pipeline Number Of Drug Candidates ProductPipelineNumberOfDrugCandidates	3
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	5100000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	2200000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	400000
CY2019	chrs	Write Off Of Prepaid Manufacturing Costs WriteOffOfPrepaidManufacturingCosts	1300000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the recent COVID-19 outbreak could have on the Company’s significant accounting estimates. Accounting estimates and judgements are inherently uncertain and the actual results could differ from these estimates.</p>
CY2021	chrs	Number Of Operating And Reportable Segments NumberOfOperatingAndReportableSegments	1
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	541158000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177668000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72356000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	440000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	240000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	835000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	541598000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177908000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73191000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	417195000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	541158000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177668000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	440000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	440000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	240000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	417635000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	541598000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177908000
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	Payment terms differ by jurisdiction and customer, but payment terms typically range from 30 to 67 days from date of shipment.
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1400000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	600000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	1600000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Risk</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash, cash equivalents and investments by </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">investing in a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company’s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. There were no material losses from credit risks on such accounts during any of the periods presented. The Company is not exposed to any significant concentrations of credit risk from these financial instruments.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to credit risk from trade receivables related to product sales and monitors the credit worthiness of customers that are granted credit in the normal course of business. In general, there is no requirement for collateral from customers. The Company has not experienced significant losses with respect to the collection of trade receivables. The Company believes that its allowance for expected credit losses was adequate at December 31, 2021.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a strategic commercial supply agreement with KBI Biopharma for the supply of UDENYCA. The Company currently has not engaged back-up suppliers or vendors for this single-sourced service. If KBI Biopharma is not able to manufacture the supply needed in the quantities and timeframe required, the Company may not be able to supply the product in a timely manner.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s revenues are in the United States to three wholesalers. UDENYCA is currently the only product sold by the Company and accounted for all of the Company’s revenues in 2021, 2020 and 2019.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has no significant monetary assets or liabilities in foreign currencies, and the Company has not had material foreign currency impacts for all years presented.</p>
CY2021	chrs	Intangible Assets Measured At Fair Value At Acquisition Date Subject To Adjustment Measurement Period IntangibleAssetsMeasuredAtFairValueAtAcquisitionDateSubjectToAdjustmentMeasurementPeriod	P1Y
CY2019Q3	chrs	Royalty Payment Term RoyaltyPaymentTerm	P5Y
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	8700000
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	3800000
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	4500000
CY2021Q4	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P36M
CY2020Q4	chrs	Reserve For Discounts And Allowances Constitute Variable Consideration ReserveForDiscountsAndAllowancesConstituteVariableConsideration	123398000
CY2021	chrs	Reserve For Sales Discounts And Allowances Constitute Variable Consideration ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration	679199000
CY2021	chrs	Provision Related To Sales Made In Prior Period ProvisionRelatedToSalesMadeInPriorPeriod	-11407000
CY2021	chrs	Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration	681467000
CY2021Q4	chrs	Reserve For Discounts And Allowances Constitute Variable Consideration ReserveForDiscountsAndAllowancesConstituteVariableConsideration	109723000
CY2019Q4	chrs	Reserve For Discounts And Allowances Constitute Variable Consideration ReserveForDiscountsAndAllowancesConstituteVariableConsideration	87147000
CY2020	chrs	Reserve For Sales Discounts And Allowances Constitute Variable Consideration ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration	692564000
CY2020	chrs	Provision Related To Sales Made In Prior Period ProvisionRelatedToSalesMadeInPriorPeriod	-11062000
CY2020	chrs	Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration	645251000
CY2020Q4	chrs	Reserve For Discounts And Allowances Constitute Variable Consideration ReserveForDiscountsAndAllowancesConstituteVariableConsideration	123398000
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2016Q1	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	9000000.0
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4870000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5205000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	65117000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	43952000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	23265000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	43032000
CY2021Q4	us-gaap	Inventory Gross InventoryGross	93252000
CY2020Q4	us-gaap	Inventory Gross InventoryGross	92189000
CY2021Q4	us-gaap	Inventory Net InventoryNet	37642000
CY2020Q4	us-gaap	Inventory Net InventoryNet	44233000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	55610000
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	47956000
CY2021Q4	chrs	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	93252000
CY2020Q4	chrs	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	92189000
CY2021Q4	chrs	Prepaid Manufacturing Expense Current PrepaidManufacturingExpenseCurrent	13700000
CY2021Q4	chrs	Prepayments Made To Cmo For Manufacturing Services PrepaymentsMadeToCmoForManufacturingServices	8300000
CY2021Q4	chrs	Prepayments Made To Cmo For Other Research And Development Pipeline Program PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram	5400000
CY2020Q4	chrs	Prepaid Manufacturing Expense Current PrepaidManufacturingExpenseCurrent	19400000
CY2020Q4	chrs	Prepayments Made To Cmo For Manufacturing Services PrepaymentsMadeToCmoForManufacturingServices	8900000
CY2020Q4	chrs	Prepayments Made To Cmo For Other Research And Development Pipeline Program PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram	10500000
CY2021	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	-3200000
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	24662000
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	26158000
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	16849000
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	16050000
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7813000
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10108000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3500000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2900000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3300000
CY2019	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0
CY2020	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0
CY2021Q4	chrs	Accrued Clinical And Manufacturing Liabilities Current AccruedClinicalAndManufacturingLiabilitiesCurrent	30541000
CY2020Q4	chrs	Accrued Clinical And Manufacturing Liabilities Current AccruedClinicalAndManufacturingLiabilitiesCurrent	11365000
CY2021Q4	chrs	Accrued Co Development Costs For Toripalimab Current AccruedCoDevelopmentCostsForToripalimabCurrent	1926000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12168000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12182000
CY2021Q4	chrs	Lease Liabilities Operating And Financing LeaseLiabilitiesOperatingAndFinancing	3492000
CY2020Q4	chrs	Lease Liabilities Operating And Financing LeaseLiabilitiesOperatingAndFinancing	3132000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	48127000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	26679000
CY2020Q2	us-gaap	Share Price SharePrice	14.815
CY2020Q2	us-gaap	Share Price SharePrice	14.815
CY2021Q4	us-gaap	Share Price SharePrice	15.96
CY2016Q1	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	15
CY2021Q4	us-gaap	Share Price SharePrice	15.96
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	27052000
CY2021Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	16300000
CY2021Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	10108000
CY2021Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	268000
CY2021Q4	us-gaap	Recorded Unconditional Purchase Obligation Due In Fifth Year RecordedUnconditionalPurchaseObligationDueInFifthYear	179000
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	53907000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8193000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9956000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1220000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1451000
CY2021Q4	chrs	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	9413000
CY2020Q4	chrs	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	11407000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2751000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2573000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6753000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9073000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9504000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11646000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	741000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	560000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	498000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	875000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1239000
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1435000
CY2021	us-gaap	Lease Cost LeaseCost	3100000
CY2020	us-gaap	Lease Cost LeaseCost	3100000
CY2019	us-gaap	Lease Cost LeaseCost	2400000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3400000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	3200000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3401000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	790000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3560000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	449000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3014000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	61000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	412000
CY2021Q4	chrs	Lessee Operating Lease Liability Payments Due Year Five And After Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive	416000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10803000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1300000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1299000
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	61000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9504000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1239000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.081
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.058
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.058
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.80
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.94
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.52
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	9700000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14600000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10300000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	61400000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M6D
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	51364000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38160000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	33591000
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1025000
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1460000
CY2019	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1735000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-42000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-287058000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	133615000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	92585000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.252
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.167
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.144
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.026
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2092000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	190000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-287100000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	135707000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	92775000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3463000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2942000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3463000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2942000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3463000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2942000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3500000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2900000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.020
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2021	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.002
CY2020	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.004
CY2019	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.006
CY2021	chrs	Effective Income Tax Rate Reconciliation Tax Expense And Credits Research EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch	0.026
CY2020	chrs	Effective Income Tax Rate Reconciliation Tax Expense And Credits Research EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch	-0.048
CY2019	chrs	Effective Income Tax Rate Reconciliation Tax Expense And Credits Research EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch	-0.048
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.012
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.013
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.013
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.007
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.032
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	117793000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	94043000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	58039000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	49965000
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	40620000
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	9672000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	30565000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	25983000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	17299000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	16404000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	11798000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	8013000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	276114000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	204080000
CY2021Q4	chrs	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2167000
CY2020Q4	chrs	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2566000
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	603000
CY2020Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	589000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2770000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3155000
CY2021Q4	chrs	Deferred Tax Asset Liability Net DeferredTaxAssetLiabilityNet	273344000
CY2020Q4	chrs	Deferred Tax Asset Liability Net DeferredTaxAssetLiabilityNet	200925000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	273344000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	200925000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	72400000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-22700000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-13400000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13243000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11603000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18115000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2038000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1749000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1206000
CY2021	chrs	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	214000
CY2020	chrs	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-109000
CY2019	chrs	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-7718000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15495000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13243000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11603000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15500000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13200000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11600000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-287100000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	132244000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	89833000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75449632
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71411705
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69679916
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.81
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.85
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.29
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-287100000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	132244000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	89833000
CY2020	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	3307000
CY2021	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-287100000
CY2020	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	135551000
CY2019	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	89833000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75449632
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71411705
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69679916
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3455646
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3491272
CY2020	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	167597
CY2019	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	14755
CY2020	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8456950
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	75449632
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	83491898
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	73185943
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.81
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.62
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.23
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38122727
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14002963
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14908410
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	800000

Files In Submission

Name	View Source	Status
0001558370-22-001764-index-headers.html	Edgar Link	pending
0001558370-22-001764-index.html	Edgar Link	pending
0001558370-22-001764.txt	Edgar Link	pending
0001558370-22-001764-xbrl.zip	Edgar Link	pending
chrs-20211231.xsd	Edgar Link	pending
chrs-20211231x10k.htm	Edgar Link	pending
chrs-20211231x10k007.jpg	Edgar Link	pending
chrs-20211231x10k_htm.xml	Edgar Link	completed
chrs-20211231xex10d32.htm	Edgar Link	pending
chrs-20211231xex23d1.htm	Edgar Link	pending
chrs-20211231xex31d1.htm	Edgar Link	pending
chrs-20211231xex31d2.htm	Edgar Link	pending
chrs-20211231xex32d1.htm	Edgar Link	pending
chrs-20211231_cal.xml	Edgar Link	unprocessable
chrs-20211231_def.xml	Edgar Link	unprocessable
chrs-20211231_lab.xml	Edgar Link	unprocessable
chrs-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHRS
Coherus BioSciences, Inc. Stock $chrs

2021 Q4 Form 10-K Financial Statement

#000155837022001764 Filed on February 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRS Coherus BioSciences, Inc. Stock $chrs

2021 Q4 Form 10-K Financial Statement

#000155837022001764 Filed on February 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRS
Coherus BioSciences, Inc. Stock $chrs